ID Biomedical Suffers Setback in Development of Streptococcal Vaccine

Drug Industry Daily
KEYWORDS FDA
A A

The FDA has requested a “significant” amount of additional data on ID Biomedical’s experimental streptococcal vaccine StreptAvax, putting a kink in the firm’s development timeline for the vaccine.

To View This Article:

Login

Subscribe To Drug Industry Daily